VIBATIV(R) (Telavancin) Shows Greater In Vitro Potency Against Difficult-to-Treat Pathogens Causing Hospital-Acquired Bacterial Pneumonia, Including MRSA, Compared to Alternative Antibiotic Treatments

DUBLIN, IRELAND--(Marketwired - Apr 11, 2016) - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that new positive data from a study of VIBATIV^® (telavancin), the Company's FDA-approved antibiotic, were the focus of a poster presentation at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Researchers collected and analyzed clinical isolates causing hospital-acquired bacterial pneumonia (HABP) in patients from around the world in 2014. Results from the study demonstrated that VIBATIV possessed potent in vitro activity against this broad range of Staphylococcus aureus (S. aureus) clinical isolates, including methicillin-resistant S. aureus (MRSA). This activity for VIBATIV was seen against 100% of the evaluated S. aureus clinical isolates regardless of their type or resistance profile. 

Furthermore, study findings demonstrated greater in vitro activity for VIBATIV against difficult-to-treat S. aureus pathogens as compared to other well-known antibiotics such as vancomycin and linezolid. This was evidenced by minimum inhibitory concentrations (MICs) for VIBATIV that were 16- to 32-fold lower than for linezolid and vancomycin against the subsets of S. aureus isolates classified as MRSA or multidrug-resistant. MICs are a measure used to express in vitro activity of an antibiotic against a pathogen and these results equate to in vitro activity for VIBATIV that was 16- to 32-times greater that these widely prescribed competitor antibiotics against some of the most difficult-to-treat Gram-positive pathogens. 

"We are pleased to continue to consistently generate study data that show important in vitro potency advantages for VIBATIV against some of the most problematic and difficult-to-treat Gram-positive clinical isolates, including MRSA, when compared to other antibiotic options. This broad and growing collection of supportive data extends across a number of serious infection types and includes a wide range of S. aureus clinical isolates regardless of classification or resistance phenotype and subset," said Frank Pasqualone, Senior Vice President and Global Head, Acute Care Business at Theravance Biopharma. "This data collection strongly supports our position that VIBATIV is a key therapeutic option when vancomycin or other therapies are not effective or appropriate for treating infections that are susceptible to VIBATIV therapy."